Publication:
Emerging concepts in drug discovery for cancer therapy.

dc.contributor.authorMurga, Matilde
dc.contributor.authorFernandez-Capetillo, Oscar
dc.contributor.funderEuropean Union (EU)es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderSwedish Research Council
dc.contributor.funderSwedish Cancer Society (Cancerfonden)
dc.date.accessioned2024-03-15T11:12:19Z
dc.date.available2024-03-15T11:12:19Z
dc.date.issued2022-11
dc.description.abstractThese are exciting times to be involved in biomedical research. The transition from a scientific hypothesis to a testable therapy is now faster than ever, and new technologies that facilitate drug development are constantly emerging. The rapid development of COVID-19 vaccines provides a clear example of the current pace of drug discovery and its clinical implementation. Importantly, the wide availability of technologies that speed up drug development has also reached oncology, and investigators can now consider several independent strategies when looking to develop a new therapy. This thematic issue provides an overview of recent advances in cancer drug discovery, in areas such as fragment-based drug development, targeting the DNA damage response or the MYC oncogene, senolytic therapies and computational tools that facilitate drug discovery and the selection of treatments in personalized medicine. We are confident that reading these reviews will help those interested in the development of cancer therapies get a broader and updated view of available opportunities and challenges.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipResearch in OF laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (PID2021-128722OB-I00, co-financed with European FEDER funds), the Spanish Association Against Cancer (AECC; PROYE20101FERN), Cancerfonden (180640) and the Swedish Research Council (538-2014-31).es_ES
dc.format.number21es_ES
dc.format.page3757es_ES
dc.format.volume16es_ES
dc.identifier.citationMol Oncol . 2022 ;16(21):3757-3760.es_ES
dc.identifier.doi10.1002/1878-0261.13325es_ES
dc.identifier.e-issn1878-0261es_ES
dc.identifier.journalMolecular oncologyes_ES
dc.identifier.pubmedID36321722es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18965
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.publisherversionhttps://doi.org/10.1002/1878-0261.13325.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómicaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshDrug Discoveryes_ES
dc.subject.meshNeoplasmses_ES
dc.subject.meshHumanses_ES
dc.titleEmerging concepts in drug discovery for cancer therapy.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication109ab297-8df3-458e-9a03-0dd210ea8e09
relation.isAuthorOfPublicationeb478d8c-dd11-4b47-8795-7ac57cb60b2d
relation.isAuthorOfPublication.latestForDiscovery109ab297-8df3-458e-9a03-0dd210ea8e09
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublication9e38e2be-00c0-4773-b81b-5d9e7cf759bb
relation.isFunderOfPublicationca471737-dd04-46d8-b64f-cde7f0ea3793
relation.isFunderOfPublication.latestForDiscovery289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Emergingconceptsindrugdiscovery_2022.pdf
Size:
163.15 KB
Format:
Adobe Portable Document Format
Description:
Artículo principal